Abstract:
:Four to 10% of patients with Parkinson disease and chronically treated with levodopa undergo an addictionlike behavioral disturbance named dopamine dysregulation syndrome (DDS). This article suggests that patients with Parkinson disease could be especially prone to develop DDS due to the dopamine deficiency and the "priming" of neural networks by the chronic use of drugs with a short half-life, such as levodopa. These suggestions are based on the clinical and molecular similarities between levodopa-induced dyskinesias and behavioral alterations seen in DDS and addiction to illegal drugs. Motor and behavioral abnormalities can be seen as the consequence of common mechanisms involving anomalous forms of neural plasticity. These forms affect parts of the cortical-basal ganglia-thalamocortical circuits that are topographically organized to differently modulate emotional and motor functions. Recent evidence using positron emission tomography provides support to this idea. By contrast, molecular data suggest that functional segregation may be lost in addiction, DDS, and dyskinesias. The existence of common pathogenic mechanisms for both phenomena could provide the basis for common therapeutic strategies.
journal_name
Clin Neuropharmacoljournal_title
Clinical neuropharmacologyauthors
Linazasoro Gdoi
10.1097/WNF.0B013E3181634EA6subject
Has Abstractpub_date
2009-01-01 00:00:00pages
22-7issue
1eissn
0362-5664issn
1537-162Xpii
00002826-200901000-00005journal_volume
32pub_type
杂志文章abstract::This study was devised to check the feasibility and validity of a rating scale specifically designed to evaluate gait impairment in Parkinson's disease (RSGE). Demographic data, a brief questionnaire on general aspects influencing gait and mobility, a battery of scales (Barthel Index; Hoehn and Yahr staging; and North...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,多中心研究
doi:10.1097/00002826-199706000-00001
更新日期:1997-06-01 00:00:00
abstract:OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/WNF.0000000000000188
更新日期:2016-11-01 00:00:00
abstract::Few studies have been published on the pharmacologic response to treatment of patients whose seizures begin after 40 years of age. The purpose of this study was to assess the impact of chronic pharmacotherapy on the seizure control of such patients. We retrospectively studied the seizure frequency recorded during a 12...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199502000-00002
更新日期:1995-02-01 00:00:00
abstract::The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-200101000-00007
更新日期:2001-01-01 00:00:00
abstract::The suppressive roles of adrenergic stimulation and rapid eye movement (REM) sleep on human prolactin (PRL) secretion are controversial. We examined the effects of sleep, clonidine (an alpha 2-adrenergic agonist), and their interaction on PRL secretion. Two groups of normal men (nine each) were studied in two morning ...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199110000-00005
更新日期:1991-10-01 00:00:00
abstract::A group of four monkeys was rendered parkinsonian with the toxin MPTP. They were then treated chronically with L-DOPA/benserazide 50/12.5 mg/kg given orally daily for 2 months. This dose produced a striking antiparkinsonian effect, but all animals manifested dyskinesia. A series of agents acting primarily on neurotran...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199310000-00004
更新日期:1993-10-01 00:00:00
abstract::The aim of the present study was to evaluate sexual function and behaviour in male patients who take lithium. Participants included 35 bipolar and schizoaffective men, aged 43.3 +/- 9.6 years, who were in euthymic state and were receiving lithium as the sole medical treatment. Eleven patients (31.4%) reported sexual d...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199619060-00005
更新日期:1996-12-01 00:00:00
abstract::Forty patients with different clinical and electrophysiological types of myoclonus were treated with piracetam (18-24 g per day, p.o.) alone, or with other drugs (clonazepam, sodium valproate, and primidone) in different combinations. Piracetam in monotherapy improved the electrophysiological abnormalities in patients...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-198812000-00006
更新日期:1988-12-01 00:00:00
abstract::Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-198802000-00004
更新日期:1988-02-01 00:00:00
abstract:OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000255
更新日期:2018-01-01 00:00:00
abstract::Infantile spasms are the main feature in West syndrome, an age-related epilepsy syndrome that affects 1 in every 2,000-4,000 infants. The authors provide a comprehensive review of the literature about infantile spasms and their therapy. In the United States, the drug of choice for infantile spasms, at least the crypto...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/00002826-200203000-00001
更新日期:2002-03-01 00:00:00
abstract::Seven of 63 children (11%) treated with clobazam (CLB) for refractory epilepsy developed a severe behavior disorder. This disorder was characterized by aggressive agitation, self injurious behavior, insomnia, and incessant motor activity occurring between 10 and 55 days after initiation of drug therapy. The affected c...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-199408000-00004
更新日期:1994-08-01 00:00:00
abstract::To investigate clinical aspects of the neutropenia induced by high-dose intravenous immunoglobulin therapy (IVIG) we performed serial hematology, including differentiation of white blood cells (WBC), before and after 22 instances of IVIG in 16 patients with neuroimmunologic disorders. WBC and neutrophils showed a sign...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-200311000-00009
更新日期:2003-11-01 00:00:00
abstract::Modafinil is a psychostimulant compound that is just now becoming available in many countries for treatment of narcoleptic and hypersomnic patients. Whereas sleep attacks and drowsiness can be effectively improved, the drug does not sufficiently reduce cataplectic seizures. It therefore is often used in combination wi...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1998-03-01 00:00:00
abstract::Myoclonic status epilepticus (MSE) in patients without epilepsy, or de novo MSE, is a rare condition associated with several acute symptomatic etiologies, including drugs and toxins. We describe a 94-year-old woman with Alzheimer dementia and long use of mirtazapine 30 mg/d and alprazolam 1 mg/d who developed MSE appr...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000283
更新日期:2018-07-01 00:00:00
abstract::trans-Dihydrolisuride, a partial dopamine receptor agonist, was tested for its effects on chorea in a double-blind, crossover clinical study in 10 patients with Huntington's disease. In eight patients, a neurophysiological evaluation was also performed. No reduction in choreic movements or improvement in voluntary mov...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-198910000-00008
更新日期:1989-10-01 00:00:00
abstract:OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000024
更新日期:2014-03-01 00:00:00
abstract::The mechanism of action of flunarizine (FZ) and cinnarizine (CZ) on the CNS is not fully understood. Computer analysis of saccadic eye movements (SEM) provides a sensitive and objective method for evaluating drug effect on the function of specific brain structures. This study aimed to assess the effect of a single ora...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1097/00002826-199410000-00003
更新日期:1994-10-01 00:00:00
abstract::Tolcapone, a central and peripheral catechol O-methyltransferase (COMT) inhibitor, reduces the conversion of L-Dopa into 3-O-methyl-Dopa (3-OMD), thus leading to more stable and sustained L-Dopa plasma levels. This study was designed to evaluate the effects of acute and 6-week tolcapone administration on L-Dopa pharma...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199901000-00005
更新日期:1999-01-01 00:00:00
abstract::We studied the effect of inhibiting the enzyme catechol-O-methyltransferase (COMT) by a novel COMT inhibitor, entacapone, on the pharmacokinetics and metabolism of levodopa in 12 healthy male volunteers. Single increasing oral doses of entacapone (50-400 mg) were administered concomitantly with a single oral dose of l...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199304000-00007
更新日期:1993-04-01 00:00:00
abstract:OBJECTIVES:Persistent sequelae of lithium intoxication gained clinical attention in the 1980s and were named Syndrome of Irreversible Lithium-Effectuated Neurotoxicity (SILENT). The authors review the published cases of SILENT reported in the literature and discuss various clinical manifestations. METHODS:The authors'...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,评审
doi:10.1097/01.wnf.0000150871.52253.b7
更新日期:2005-01-01 00:00:00
abstract::To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章
doi:10.1097/00002826-200001000-00008
更新日期:2000-01-01 00:00:00
abstract::The effect and clinical significance of tolcapone withdrawal on erythrocyte catechol-O-methyltransferase (COMT) activity, levodopa pharmacokinetics, and levodopa requirements were investigated in 59 patients with fluctuating parkinsonism who were randomized to receive placebo or tolcapone 100 or 200 mg three times dai...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究,随机对照试验
doi:10.1097/00002826-200003000-00007
更新日期:2000-03-01 00:00:00
abstract::A 21-year-old patient developed rhabdomyolysis during his nineteenth week of treatment with clozapine for drug-resistant schizophrenia. No risk factors for rhabdomyolysis were found, but the calcium-dependent potassium efflux, normally responsible for membrane hyperpolarization and muscle refractoriness, was severely ...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:
更新日期:1998-07-01 00:00:00
abstract::Trazodone is a serotonin antagonist and reuptake inhibitor that is widely used for the treatment of depression and insomnia. Fatal overdose is rare and usually occurs when combined with other drugs or alcohol. Only a few lethal cases of pure trazodone overdose have been reported, all attributed to cardiotoxicity. We r...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0000000000000235
更新日期:2017-09-01 00:00:00
abstract:INTRODUCTION:The Restless Legs Syndrome is a common sensorimotor disorder, typically amenable to treatment with dopamine agonist therapy. Dopamine agonists have been associated with emergent impulse control disorders (ICDs) when used in patients with Parkinson disease, and ICDs have now been reported in individuals wit...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/WNF.0b013e31820d6699
更新日期:2011-03-01 00:00:00
abstract::Daily 20-mg doses of Copolymer 1 have been shown to significantly decrease the relapse rate in patients with multiple sclerosis (MS). In the present open-label study, patients with relapsing MS were treated with the same dose of Copolymer 1 administered on alternate days. Sixty-eight patients were recruited: fifty-one...
journal_title:Clinical neuropharmacology
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1097/00002826-200201000-00002
更新日期:2002-01-01 00:00:00
abstract::Intravenous injection of low doses of naloxone was found to reverse the respiratory depression induced by apomorphine in chloralose-anesthesized dogs. Similar results were obtained with haloperidol, whereas yohimbine remained ineffective. These data suggest that apomorphine depresses respiratory rate through a mechani...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199210000-00009
更新日期:1992-10-01 00:00:00
abstract::Acute psychotic episodes represent critical situations during the course of schizophrenia. Olanzapine (OLZ), a second-generation antipsychotic, is efficacious in acute settings at dosages of 5 to 20 mg/d, and it can be considered a first-line treatment for patients with an acute episode of schizophrenia. The aim of th...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章,随机对照试验
doi:10.1097/01.WNF.0000220819.71231.96
更新日期:2006-05-01 00:00:00
abstract::Drugs (e.g., PCP) which interfere with glutamatergic transmission at the N-methyl D-aspartate (NMDA) subclass of glutamate receptors precipitate both positive and negative symptoms of psychosis in humans. Based on a proposed "glutamatergic deficiency" in schizophrenia, pharmacologic facilitation of NMDA-mediated neura...
journal_title:Clinical neuropharmacology
pub_type: 杂志文章
doi:10.1097/00002826-199106000-00012
更新日期:1991-06-01 00:00:00